- Home
- CTRN vs CTNM Comparison
CTRN vs CTNM Comparison
Compare CTRN & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTRN
- CTNM
- Stock Information
- Founded
- CTRN 1946
- CTNM 2009
- Country
- CTRN United States
- CTNM United States
- Employees
- CTRN N/A
- CTNM N/A
- Industry
- CTRN Clothing/Shoe/Accessory Stores
- CTNM
- Sector
- CTRN Consumer Discretionary
- CTNM
- Exchange
- CTRN Nasdaq
- CTNM Nasdaq
- Market Cap
- CTRN 280.0M
- CTNM 248.7M
- IPO Year
- CTRN 2005
- CTNM 2024
- Fundamental
- Price
- CTRN $33.93
- CTNM $12.36
- Analyst Decision
- CTRN Buy
- CTNM Strong Buy
- Analyst Count
- CTRN 2
- CTNM 4
- Target Price
- CTRN $31.50
- CTNM $22.75
- AVG Volume (30 Days)
- CTRN 102.1K
- CTNM 278.0K
- Earning Date
- CTRN 08-26-2025
- CTNM 11-05-2025
- Dividend Yield
- CTRN N/A
- CTNM N/A
- EPS Growth
- CTRN N/A
- CTNM N/A
- EPS
- CTRN N/A
- CTNM N/A
- Revenue
- CTRN $782,716,000.00
- CTNM N/A
- Revenue This Year
- CTRN $6.80
- CTNM N/A
- Revenue Next Year
- CTRN $4.61
- CTNM N/A
- P/E Ratio
- CTRN N/A
- CTNM N/A
- Revenue Growth
- CTRN 3.32
- CTNM N/A
- 52 Week Low
- CTRN $14.91
- CTNM $3.35
- 52 Week High
- CTRN $39.37
- CTNM $20.30
- Technical
- Relative Strength Index (RSI)
- CTRN 49.08
- CTNM 73.06
- Support Level
- CTRN $34.35
- CTNM $10.30
- Resistance Level
- CTRN $39.37
- CTNM $13.26
- Average True Range (ATR)
- CTRN 2.37
- CTNM 1.04
- MACD
- CTRN -0.34
- CTNM 0.03
- Stochastic Oscillator
- CTRN 27.37
- CTNM 77.13
About CTRN Citi Trends Inc.
Citi Trends Inc is a retailer of urban fashion apparel and accessories in the United States. The company offers apparel, including fashion sportswear for men and women, as well as children, such as newborns, infants, toddlers, boys, and girls; accessories comprising handbags, jewelry, footwear, belts, intimate apparel, scrubs, and sleepwear; and functional and decorative home products, as well as beauty products, books and toys.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.